. 2020 Oct 21;4(5):bjgpopen20X101087. doi: 10.3399/bjgpopen20X101087

Table 2. Characteristics of included studies.

Authors	Study title	Cardiovascular drug	Health professionals, n	Patients, n	Study design	Data collection	Data analysis	Quality of study
UK
Gale, 2011 ¹⁸	Attitudes of patients and GPs towards medication for primary prevention of CVD after they had received detailed information about CVD risk and the absolute benefits of preventive medicine.	Cardiovascular preventive drugs (statin and antihypertensive drugs)	13	17	Qualitative	Patients: face to face interviewsGPs: interviews	Thematic analysis	Good
Turner, 2013 ³⁴	Reasons for the variation in statin uptake by high risk patients	Statin	4	28	Qualitative	Patients: 10 minutes telephone interviews.GPs: 30 minutes face to face interviews.	Thematic analysis	Fair
Virdee, 2013 ³²	Primary care physicians’ and practice nurses’ attitude towards using the polypill for CVD prevention	Polypill	16 (11 physicians, five practice nurses)	–	Qualitative	Semi-structured interviews and transcribed verbatim.	Thematic analysis.	Good
Virdee, 2015 ³³	Patient attitudes about the use of a polypill for CVD prevention	Polypill	–	17	Qualitative	Semi-structured interviews.	Thematic analysis.	Good
Sweden
Hultberg, 2012 ³¹	GPs’ descriptions of their thoughts and actions when prescribing cardiovascular preventive drugs	Cardiovascular preventive drugs (no mention of specific drugs)	14	–	Qualitative	Group interviews of GPs practising together.	Qualitative content analysis.	Good